US 11,987,564 B2
PTPRD inhibitors and uses thereof
George Richard Uhl, Albuquerque, NM (US); Ian M. Henderson, Sandia Park, NM (US); Wei Wang, Tucson, AZ (US); and Thomas Prisinzano, Lexington, KY (US)
Assigned to Arizona Board of Regents on Behalf of the University of Arizona, Tucson, AZ (US); The United States Government as respresented by the Department of Veterans Affairs, Washington, DC (US); and The University of Kentucky Research Foundation, Lexington, KY (US)
Filed by United States Government as represented by the Department of Veterans Affairs, Washington, DC (US)
Filed on May 2, 2022, as Appl. No. 17/734,897.
Claims priority of provisional application 63/182,532, filed on Apr. 30, 2021.
Prior Publication US 2022/0380332 A1, Dec. 1, 2022
Int. Cl. C07D 311/54 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01)
CPC C07D 311/54 (2013.01) [C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01)] 16 Claims
 
1. A compound having a structure represented by Formula (I):

OG Complex Work Unit Chemistry
wherein R1 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxy, C2-C4 haloalkoxy, C1-C4 alkylamino, C1-C4 acetyl, or (C1-C4)(C1-C4) dialkylamino;
R2 is C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxy, C2-C4 haloalkoxy, C1-C4 alkylamino, or (C1-C4)(C1-C4) dialkylamino;
R3 is hydrogen or has a structure represented by the formula:

OG Complex Work Unit Chemistry
wherein R9-R13, when present, are independently hydrogen, methyl, —OCH3, —CN, —CF3, —OCF3, or halide;
R14, when present, is hydrogen or halide;
R15, when present, is methyl or halide;
Y, when present, is CH or N; and
R16-18, when present, are independently hydrogen, hydroxyl, or halide;
or a pharmaceutically acceptable salt thereof,
provided that when R1 is hydrogen and R2 is methyl, then R3 is not

OG Complex Work Unit Chemistry